F16 131I

Drug Profile

F16 131I

Alternative Names: 131I-F16SIP; F16-131 I; Tenarad

Latest Information Update: 30 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Philogen
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Haematological malignancies; Solid tumours

Most Recent Events

  • 30 Sep 2015 No recent reports of development identified - Phase-I/II for Haematological malignancies in Italy (Parenteral)
  • 30 Sep 2015 No recent reports of development identified - Phase-I/II for Solid tumours in Italy (Parenteral)
  • 01 Apr 2013 Philogen completes a phase I/II trial for solid tumours and haematological malignancies in Italy (NCT01240720)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top